These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 37173937)

  • 1. Metronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors.
    Muraro E; Vinante L; Fratta E; Bearz A; Höfler D; Steffan A; Baboci L
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mathematical model to study low-dose metronomic scheduling for chemotherapy.
    Arora G; Bairagi N; Chatterjee S
    Math Biosci; 2024 Jun; 372():109186. PubMed ID: 38580078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic chemotherapy: new rationale for new directions.
    Pasquier E; Kavallaris M; André N
    Nat Rev Clin Oncol; 2010 Aug; 7(8):455-65. PubMed ID: 20531380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.
    Kareva I; Waxman DJ; Lakka Klement G
    Cancer Lett; 2015 Mar; 358(2):100-106. PubMed ID: 25541061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
    Kerbel RS
    Cancer Res Treat; 2007 Dec; 39(4):150-9. PubMed ID: 19746237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment.
    Chung SW; Kim GC; Kweon S; Lee H; Choi JU; Mahmud F; Chang HW; Kim JW; Son WC; Kim SY; Byun Y
    Biomaterials; 2018 Nov; 182():35-43. PubMed ID: 30103170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic scheduling: the future of chemotherapy?
    Gasparini G
    Lancet Oncol; 2001 Dec; 2(12):733-40. PubMed ID: 11902515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
    Norrby K
    APMIS; 2014 Jul; 122(7):565-79. PubMed ID: 24164171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ATP-binding cassette transporters in tumor endothelial cells and resistance to metronomic chemotherapy.
    Hida K; Kikuchi H; Maishi N; Hida Y
    Cancer Lett; 2017 Aug; 400():305-310. PubMed ID: 28216371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
    Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
    J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC
    Vergnenegre A; Monnet I; Bizieux A; Bernardi M; Chiapa AM; Léna H; Chouaïd C; Robinet G
    Future Oncol; 2020 Feb; 16(4):5-10. PubMed ID: 31894704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Benelli R; Monteghirfo S; Balbi C; Barboro P; Ferrari N
    Int J Cancer; 2009 Jun; 124(12):2989-96. PubMed ID: 19319982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.
    Lai V; Neshat SY; Rakoski A; Pitingolo J; Doloff JC
    Adv Drug Deliv Rev; 2021 Dec; 179():113920. PubMed ID: 34384826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of vascular normalization in benefit from metronomic chemotherapy.
    Mpekris F; Baish JW; Stylianopoulos T; Jain RK
    Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1994-1999. PubMed ID: 28174262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.